Most Favored Patient Act of 2026
To amend title XI of the Social Security Act to require the Center for Medicare and Medicaid Innovation to test a model implementing most-favored-nation drug pricing.
HB7837, also known as the Most Favored Patient Act of 2026, seeks to make changes to the Social Security Act by requiring the Center for Medicare and Medicaid Innovation to test a model that implements most-favored-nation drug pricing. This means that the bill aims to ensure that the prices for prescription drugs in the U.S. are as competitive as those in other countries where the U.S. has agreements.
The bill would primarily affect patients, healthcare providers, and pharmaceutical companies. By ensuring that drug prices in the U.S. are competitive with those in other countries, it could potentially lower the cost of prescription drugs for patients and the healthcare system.
As of March 5, 2026, the bill was introduced in the House and referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for further consideration. The bill is currently in its early stages of the legislative process.
